ITEM 2.02. -RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

Beginning on January 9, 2023, ImmunoGen, Inc. (the "Company") intends to use a corporate presentation (the "Corporate Presentation) at the 41st Annual JP Morgan Healthcare Conference in one or more meetings with or presentations to investors. The Corporate Presentation contains certain information regarding the Company's expected financial condition as of December 31, 2022 and financial results for 2022, as well as other updates on its business activities. A copy of the Corporate Presentation is furnished as Exhibit 99.1.

The information in this Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01. - FINANCIAL STATEMENTS AND EXHIBITS.



(d): Exhibits

Exhibit No.      Description

99.1               Corporate Presentation for 41st Annual JP Morgan Healthcare
                 Conference

104              Cover Page Interactive Data File (embedded within the Inline XBRL
                 (eXtensible Business Reporting Language) document)

© Edgar Online, source Glimpses